Can you take Brentuximab with Somatrogon?

Somatrogon has a major potential interaction with Acute Abdomen.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Somatrogon has a major potential interaction with Bladder Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a major potential interaction with Brain Tumor.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a major potential interaction with Breast Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Diabetes Mellitus.

Serious events of hyperglycemia (e.g., new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, ketoacidosis [including fatalities]) have been reported in brentuximab vedotin-treated patients. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Serum glucose should be monitored and if hyperglycemia develops, antihyperglycemic agents should be administered as clinically indicated.

Somatrogon has a moderate potential interaction with Diabetes Mellitus.

Somatrogon may increase the risk of diabetes mellitus (DM) in patients with Turner syndrome. Monitor blood glucose levels periodically to assess for new onset diabetes in these patients. In patients with Turner syndrome and preexisting DM, monitor blood glucose more closely as adjustment of antidiabetic agents may be required when somatrogon is initiated.

Somatrogon has a moderate potential interaction with Diabetes Mellitus.

Treatment with growth hormone may decrease insulin sensitivity, inducing a state of insulin resistance and hyperglycemia, especially at higher doses. New onset type 2 diabetes mellitus (DM) or worsened glycemic control in patients with undiagnosed pre-diabetes or DM has been reported in patients receiving growth hormone. Monitor glucose levels in all patients during therapy with somatrogon, especially in those with who have glucose intolerance, or additional risk factors for diabetes (e.g., obesity, Turner syndrome, family history). Initiation of somatrogon in patients who have type 1 or 2 diabetes mellitus may require dose adjustment of anti-diabetic therapy.

Somatrogon has a major potential interaction with Diabetic Retinopathy.

Somatropin, somatrogon , and lonapegsomatropin are contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy since treatment may worsen condition.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Gastrointestinal Obstruction.

Fatal and serious events of acute pancreatitis have been reported with brentuximab vedotin. Other fatal and serious gastrointestinal (GI) complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. If new or worsening GI symptoms (including severe abdominal pain) develop, it is recommended to perform a prompt diagnostic evaluation and treat appropriately.

The brentuximab vedotin in brentuximab has a major potential interaction with Infection.

Serious infections and opportunistic infections (e.g., pneumonia, bacteremia, sepsis/septic shock [including fatalities]) have been reported in patients treated with brentuximab vedotin. Patients should be monitored closely for the emergence of any infection during treatment with this agent. John Cunningham virus (JC virus) infection resulting in progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with this agent. A diagnosis of PML should be considered in any patient presenting with new-onset signs/symptoms of CNS abnormalities. Therapy should be held for any suspected case of PML and discontinued if a diagnosis of PML is confirmed.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Liver Disease.

The use of brentuximab vedotin should be avoided in patients with moderate or severe liver dysfunction (Child-Pugh B or C). The frequency of grade 3 or higher adverse reactions and deaths was greater in patients with moderate and severe liver dysfunction compared to those with normal liver function. Fatal and serious cases of hepatotoxicity have occurred in patients receiving this agent. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Liver enzymes and bilirubin should be monitored. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of brentuximab vedotin.

Somatrogon has a major potential interaction with Lung Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a moderate potential interaction with Papilledema Associated with Increased Intracranial Pressure.

Intracranial hypertension with papilledema, visual changes, nausea and/or vomiting has been reported in a small number of patients treated with somatropin, somatrogon , and lonapegsomatropin . Fundoscopic examination should be performed before treatment initiation to exclude preexisting papilledema, and should be continued periodically during treatment. If papilledema is observed during treatment, therapy should be stopped. Treatment could be restarted at a lower dose once intracranial hypertension has been resolved. Patients with Turner Syndrome might be at increased risk of developing intracranial hypertension.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Peripheral Neuropathy.

Peripheral neuropathy, predominantly sensory neuropathy, has occurred in patients treated with brentuximab vedotin. Patients should be monitored for symptoms of neuropathy, and those experiencing new or worsening peripheral neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin.

Somatrogon has a major potential interaction with Prostate Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a major potential interaction with Pulmonary Impairment.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

Somatrogon has a major potential interaction with Pulmonary Impairment.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Pulmonary Impairment.

Fatal and serious events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported with the use of brentuximab vedotin. Care should be taken when using this agent in patients at risk of pulmonary events. Patients should be monitored for signs/symptoms of pulmonary toxicity (including cough and dyspnea). If new or worsening pulmonary symptoms develop, brentuximab vedotin dosing should be held during evaluation and until symptomatic improvement.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Renal Dysfunction.

The use of brentuximab vedotin should be avoided in patients with severe renal dysfunction (CrCl less than 30 mL/min). The frequency of grade 3 or higher adverse reactions and deaths was greater in patients with severe renal dysfunction compared to those with normal renal function.

Somatrogon has a moderate potential interaction with Scoliosis.

Progression of scoliosis can occur in patients who experience rapid growth. Since somatropin and somatrogon increase growth rate, children with a history of scoliosis should be monitored for progression of this condition. Physicians should be alert for this skeletal abnormality which can be commonly seen in patients with Turner and Prader-Willi syndromes, and can manifest during somatropin and somatrogon treatment.

Somatrogon has a major potential interaction with Sepsis.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Somatrogon has a major potential interaction with Skin Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a major potential interaction with Sleep Apnea.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

The brentuximab vedotin in brentuximab has a major potential interaction with Tumor Lysis Syndrome.

Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has occurred in patients receiving certain monoclonal antibodies. Patients with high tumor burden and/or high circulating lymphocyte counts (greater than 25 x 10[9]/L) are at greater risk for developing TLS. Tumor lysis prophylaxis with anti-hyperuricemics and hydration prior to infusion may be recommended or should be considered. Electrolyte abnormalities should be corrected, and renal function and fluid balance should be monitored in patients who develop TLS. It is recommended to monitor for signs/symptoms of TLS, and temporary interruption or discontinuation of therapy might be required.

Somatrogon has a moderate potential interaction with Turner Syndrome.

Somatrogon may increase the risk of diabetes mellitus (DM) in patients with Turner syndrome. Monitor blood glucose levels periodically to assess for new onset diabetes in these patients. In patients with Turner syndrome and preexisting DM, monitor blood glucose more closely as adjustment of antidiabetic agents may be required when somatrogon is initiated.

Somatrogon has a moderate potential interaction with Turner Syndrome.

Treatment with growth hormone may decrease insulin sensitivity, inducing a state of insulin resistance and hyperglycemia, especially at higher doses. New onset type 2 diabetes mellitus (DM) or worsened glycemic control in patients with undiagnosed pre-diabetes or DM has been reported in patients receiving growth hormone. Monitor glucose levels in all patients during therapy with somatrogon, especially in those with who have glucose intolerance, or additional risk factors for diabetes (e.g., obesity, Turner syndrome, family history). Initiation of somatrogon in patients who have type 1 or 2 diabetes mellitus may require dose adjustment of anti-diabetic therapy.

Somatrogon has a major potential interaction with Weight Loss.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Weight Loss.

Serious events of hyperglycemia (e.g., new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, ketoacidosis [including fatalities]) have been reported in brentuximab vedotin-treated patients. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Serum glucose should be monitored and if hyperglycemia develops, antihyperglycemic agents should be administered as clinically indicated.

Somatrogon has a moderate potential interaction with Weight Loss.

Treatment with growth hormone may decrease insulin sensitivity, inducing a state of insulin resistance and hyperglycemia, especially at higher doses. New onset type 2 diabetes mellitus (DM) or worsened glycemic control in patients with undiagnosed pre-diabetes or DM has been reported in patients receiving growth hormone. Monitor glucose levels in all patients during therapy with somatrogon, especially in those with who have glucose intolerance, or additional risk factors for diabetes (e.g., obesity, Turner syndrome, family history). Initiation of somatrogon in patients who have type 1 or 2 diabetes mellitus may require dose adjustment of anti-diabetic therapy.